US 9050343
Combination of pimavanserin and risperidone for the treatment of psychosis
granted A61KA61K31/00A61K31/435
Quick answer
US patent 9050343 (Combination of pimavanserin and risperidone for the treatment of psychosis) held by ACADIA Pharmaceuticals Inc. expires Mon Jun 04 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ACADIA Pharmaceuticals Inc.
- Grant date
- Tue Jun 09 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 04 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/00, A61K31/435, A61K31/4468, A61K31/451